Form 8-K ELITE PHARMACEUTICALS For: Dec 02
- Wall Street gains evaporate, S&P 500 ends lower on Fed tightening timeline
- Tesla (TSLA) Reports Strong Q4 Beat, Achieves Record Vehicle Deliveries in 2021
- Intel (INTC) Reports Q4 Beat, Shares Down 2% on Guidance Miss
- Fed maintains federal funds rate at 0 to 1/4 percent, reduces assets purchases by another $30 billion/month and sees ending them in March
- Ackman Says Pershing Square Bought Over 3.1M Shares of Netflix (NFLX)
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction||(Commission||(IRS Employer|
|of incorporation)||File Number)||Identification No.)|
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
Item 1.01 Entry Into A Material Definitive Agreement
On October 18, 2021, Elite Pharmaceuticals Inc. (“Elite”) renewed its License, Supply and Distribution Agreement with Lannett Company, Inc., (“Lannett”) to market Elite’s generic Dantrolene Capsules 25 mg, 50 mg, and 100 mg in the United States. Lannett will continue to be the exclusive U.S. distributor for the generic product owned by Elite. The First Renewal Term shall be from April 9, 2022 until April 8, 2024.
Item 9.01 Financial Statements and Exhibits.
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: December 2, 2021||ELITE PHARMACEUTICALS, INC.|
|By:||/s/ Nasrat Hakim|
|Nasrat Hakim, President and CEO|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 25 Satellites Are On the Way, Don't Miss the Growth Opportunity of HKATG
- Bragar Eagel & Squire, P.C. Is Investigating TaskUs, Tecnoglass, WeWork, and Embark and Encourages Investors to Contact the Firm
- Zymeworks Announces Pricing of $100.0 Million Public Offering
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!